<DOC>
	<DOCNO>NCT03062358</DOCNO>
	<brief_summary>The purpose study determine efficacy safety pembrolizumab placebo give best supportive care ( BSC ) Asian participant previously systemically treat advanced hepatocellular carcinoma ( HCC ) . The primary hypothesis study overall survival prolong participant receive pembrolizumab compare receive placebo .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Placebo Given With Best Supportive Care Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma ( MK-3475-394/KEYNOTE-394 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Has HCC diagnosis confirm radiology , histology , cytology ( fibrolamellar , mixed hepatocellular/cholangiocarcinoma subtypes eligible ) Has Barcelona Clinic Liver Cancer ( BCLC ) Stage C disease BCLC Stage B disease amenable locoregional therapy refractory locoregional therapy amenable curative treatment approach Has ChildPugh A liver score within 7 day prior first dose study medication Has life expectancy &gt; 3 month Has least one measurable lesion base RECIST version 1.1 determine investigator Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 perform within 7 day prior receive first dose study medication Has document objective radiographic progression treatment sorafenib oxaliplatinbased chemotherapy , else intolerance sorafenib oxaliplatinbased chemotherapy Female participant childbearing potential must negative urine serum pregnancy test within 72 hour prior receive first dose study therapy Female male participant reproductive potential must agree use adequate contraception start first dose study medication , throughout study period , 120 day last dose study medication Is currently participate participate study investigational agent use investigational device within 4 week first dose study medication Has receive sorafenib oxaliplatinbased chemotherapy within 14 day first dose study medication Has esophageal gastric variceal bleeding within last 6 month Has clinically apparent ascites physical examination Has portal vein invasion main portal branch ( Vp4 ) , inferior vena cava , cardiac involvement HCC base imaging Has clinically diagnose hepatic encephalopathy last 6 month Has solid organ hematologic transplant Has prior systemic therapy HCC advance ( incurable ) set sorafenib oxaliplatinbased chemotherapy , prior start study medication Has active autoimmune disease require systemic treatment past 2 year . Replacement therapy consider form systemic treatment . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study medication Has receive locoregional therapy liver ( transcatheter chemoembolization [ TACE ] , transcatheter embolization [ TAE ] , hepatic arterial infusion [ HAI ] , radiation , radioembolization , ablation ) site within 4 week prior first dose study medication Has major surgery liver site within 4 week prior first dose study medication Has minor surgery ≤7 day prior first dose study medication Has recover adequately ( i.e. , Grade ≤1 baseline ) toxicity and/or complication intervention prior study start Has diagnose additional malignancy within 3 year prior first dose study medication exception curatively treat basal cell carcinoma skin , squamous cell carcinoma skin and/or curatively resect situ cancer Has know history , evidence , central nervous system ( CNS ) metastases and/or carcinomatous meningitis Has history ( noninfectious ) pneumonitis require steroid current pneumonitis Has active infection require systemic therapy Is pregnant breast feeding expect conceive father start first dose study medication , throughout study period , 120 day last dose study medication Has receive prior immunotherapy antiProgrammed Cell Death Receptor 1 ( PD1 ) , Programmed Cell Death Receptor Ligand 1 ( antiPDL1 ) , anti Programmed Cell Death Receptor Ligand 2 ( PDL2 ) previously participate clinical study pembrolizumab Has know history human immunodeficiency virus ( HIV ) Has untreated active Hepatitis B Has hepatitis C participant receive therapy HCV &lt; 4 week prior receive pembrolizumab Has receive live vaccine within 30 day prior first dose study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Programmed Cell Death Receptor 1 ( PD-1 )</keyword>
	<keyword>Programmed Cell Death Receptor Ligand 1 ( PD-L1 )</keyword>
	<keyword>Programmed Cell Death Receptor Ligand 2 ( PD-L2 )</keyword>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL2</keyword>
</DOC>